Sir, Lympro will be "changing the math" soon. I am "extremely pleased" with our "robust" pipeline. We will be dominating the Alzheimer's "space" soon by offering a "suite" of diagnostic tests.

"Non-dilutive funding" will only "unlock shareholder value" along with other "catalysts."

Any questions?

Cheers.